Hepsal

Hepsal is a prescription‑only intravenous medication that contains heparin sodium as its active ingredient. The product is marketed in the European Union, but specific strength and dosage‑form details are not disclosed in the available information. Hepsal belongs to the anticoagulant drug class and is used under medical supervision to influence blood clotting mechanisms.

Hepsal is employed in clinical settings where inhibition of clot formation is required. It is commonly used for: - Prevention of venous thromboembolism in patients undergoing orthopedic or abdominal surgery. - Treatment of acute deep‑vein thrombosis and pulmonary embolism. - Prophylaxis of clot formation during hemodialysis or extracorporeal circulation. - Maintaining catheter patency by preventing intraluminal thrombosis. - Managing hypercoagulable states in hospitalized patients.

Hepsal may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common: - Minor bleeding at injection site or from mucous membranes. - Small bruises or hematomas. - Nausea or mild abdominal discomfort. - Transient elevation of liver enzymes. - Mild headache.

Serious: - Major hemorrhage, including gastrointestinal or intracranial bleeding. - Heparin‑induced thrombocytopenia (HIT). - Severe allergic reactions such as anaphylaxis. - Spontaneous spinal or epidural hematoma. - Acute renal failure secondary to bleeding complications.

Use of Hepsal requires careful assessment of bleeding risk and patient history. Important considerations include: - Baseline and periodic monitoring of platelet counts to detect heparin‑induced thrombocytopenia. - Regular assessment of coagulation parameters (e.g., activated partial thromboplastin time). - Caution in patients with a history of recent surgery, trauma, or active bleeding. - Adjust dosing in individuals with renal impairment or hepatic dysfunction. - Avoid use in patients with known hypersensitivity to heparin or pork‑derived products. - Pregnancy and lactation status should be evaluated, as safety data are limited.

Hepsal can interact with several medications that affect hemostasis or renal clearance. Interaction guidance includes:

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring. - Administration with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs, which may increase bleeding risk. - Combination with thrombolytic therapy (e.g., alteplase) due to additive hemorrhagic potential.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may impair platelet function. - Certain antibiotics (e.g., cefotetan) that have been associated with HIT. - High‑dose corticosteroids, which may affect coagulation balance. - Renally cleared drugs that could accumulate if renal function declines during therapy.